Business Wire

Pricefx Announces Settlement of Intellectual Property Lawsuit

Share

Pricefx, the global leader in native cloud pricing software, has settled all outstanding worldwide litigation with Vendavo, including claims of intellectual property infringement that each company made against the other.

“We are pleased to settle all disputes and direct all of our attention to serving our customers and continuing to provide the best SaaS-based pricing software on the market. We are confident that customers and business partners of both Pricefx and Vendavo will be pleased this dispute has come to an end and both companies can focus on their individual strengths and fair competition in the marketplace,” said Marcin Cichon, CEO and co-founder of Pricefx.

The litigation between Pricefx and Vendavo began when Vendavo filed a complaint in California federal court in December 2017. From there, the case expanded and included several counterclaims by Pricefx against Vendavo for trade secret misappropriation, as well as an ancillary suit in Illinois federal court, and challenges by Pricefx to Vendavo’s patents in the U.S. Patent Office.

Aaron Werner, General Counsel of Pricefx, went on to state, “The parties’ settlement recognizes that Pricefx is the undisputed owner of all of its software and intellectual property and Pricefx’s products and services do not infringe on any of Vendavo’s intellectual property rights.”

Whereas other legacy pricing software companies provide primarily on-premises solutions, Pricefx will continue its commitment to expanding its world-leading cloud-based pricing platform that offers customers both flexibility and comprehensive functionality.

“We are pleased Pricefx is able to permanently put this dispute behind it and focus all of its efforts on continuing to be the market innovator in pricing software,” said Axel Krieger, Board Member of Pricefx and Managing Director/Founding Partner of Digital+ Partners.

Ron Kermisch, Board Member of Pricefx and Bain & Company’s global pricing leader, said, “We continue to believe Pricefx’s best days are ahead and we look forward to partnering with Pricefx’s agile and flexible platform.”

This settlement comes on the heels of several recent awards for Pricefx, including being the first C/4 HANA independent solution vendor (ISV) to reach Gold-level status for SAP® PartnerEdge® Build. Pricefx also recently won the prestigious 2019 SAMMY award from the Business Intelligence Group, as the only pricing software vendor driving major change in sales and marketing organizations worldwide.

About Pricefx

Established in 2011 in Munich, Pricefx provides a modular SaaS solution for Price Optimization, Management (PO&M) and Configure-Price-Quote (CPQ) for enterprises of any size, based on the latest native cloud architecture. The company currently serves over 110 global, blue-chip B2B and B2C customers across a variety of industries. Pricefx’s best-in-class service offering helps its customers realize an unparallel time-to-value on their pricing projects.

Pricefx has developed a strong partner ecosystem with leading global technology, consulting and integration providers - including Bain & Company and SAP®. Pricefx is a proud member of the Bain Alliance Ecosystem - a network of best-of-breed partnerships with complementary tool, technology and service providers that accelerate delivery of breakthrough client results.

For more information, please visit www.pricefx.com.

Contact information

Patrick Moorhead
Pricefx
patrick.moorhead@pricefx.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Post Malone and Crocs Launch Fourth Collaboration9.12.2019 20:57:00 EETPress release

Crocs, Inc. (NASDAQ: CROX), a global leader in innovative, casual footwear for women, men and children, today announced their latest product collaboration with multi-platinum recording artist Post Malone. This ground-breaking fourth installment of the Post Malone x Crocs collaboration series features the Post Malone x Crocs Duet Max Clog, an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005664/en/ The Post Malone x Crocs Duet Max Clog is an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This is the fourth collaboration between the duo. (Photo: Business Wire) The evolution of the Post Malone x Crocs partnership is evident over th

Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting9.12.2019 20:00:00 EETPress release

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today presented data characterizing KB-3061, the lead molecule in the Company’s Kv7 ion channel platform, at the American Epilepsy Society’s (AES) 2019 Annual Meeting in Baltimore, Maryland. Knopp is advancing the development of KB-3061 as a potential precision medicine treatment for the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE), a genetically defined disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay. The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development. Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE. K

Murray Energy Corporation Posts Information to its Website Related to Murray Metallurgical9.12.2019 18:46:00 EETPress release

Beginning on December 2, 2019, Murray Energy Corporation (the “Company”) engaged in confidential discussions under separate confidentiality agreements with certain members of an ad hoc group of superpriority lenders related Murray Metallurgical Coal Holdings, LLC and its subsidiaries (collectively, “Murray Metallurgical”). The confidentiality agreements require the Company to publicly disclose all material non-public information provided to such lenders on or prior to 8:30am (New York time) on December 9, 2019. The Company has posted certain previously undisclosed material to its website to satisfy its disclosure obligations under the confidentiality agreements. Such information can be viewed at the Investors portion of the Company’s website, located at murrayenergycorp.com/investors. Further inquiries should be directed to media@coalsource.com. Safe Harbor Statement The materials referenced in this release and posted to our website include forward-looking statements. A variety of fact

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting9.12.2019 18:00:00 EETPress release

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005169/en/ The ECHELON-1 analysis highlighted a four-year update of the phase 3 clinical trial in a poster presentation. ECHELON-1 is evaluating ADCETRIS in combination with AVD (Adriamycin [doxorubicin], vinblastine and dacarbazine) compared to ABVD (Adriamycin [doxorubicin], bleomycin, vinblasti

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 20199.12.2019 18:00:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic Factor (Recombinant), PEGylated]: In the poster “Real-World Age-Stratified FVIII Consumption and Bleed Outcom

Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding9.12.2019 17:39:00 EETPress release

Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256). The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II:

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom